Value of a complete or partial remission in severe lupus nephritis.
نویسندگان
چکیده
BACKGROUND AND OBJECTIVES The value of a complete remission in severe lupus nephritis is well known but little is known about the impact of a partial remission in this patient population. The purpose of this study was to evaluate the long-term prognosis of achieving a complete or partial remission in a well-defined group of patients with severe lupus nephritis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS In this study, 86 patients with diffuse lupus glomerulonephritis were reviewed for assessment of the value of a partial remission (50% reduction in baseline proteinuria to < or =1.5 g/d and < or =25% increase in baseline creatinine) and complete remission (proteinuria < or =0.33 g/d and serum creatinine < or =1.4 mg/dl) on outcomes compared with patients who did not attain a remission. These well-characterized patients were entered into a prospective therapeutic trial conducted by the Collaborative Study Group and were followed for more than 10 yr. RESULTS All biopsies showed diffuse lupus nephritis. A complete remission was attained in 37 (43%) patients, a partial remission in 21 (24%) patients, and no remission in 28 (32%) patients. Baseline clinical and serologic features were similar among the groups, but patients with a complete remission had a lower serum creatinine and chronicity index compared with patients with partial or no remission. The patient survival at 10 yr was 95% for complete remission, 76% for partial remission, and 46% for no remission. The renal survival at 10 yr was 94% for complete remission, 45% for partial remission, and 19% for no remission, and the patient survival without end-stage renal disease at 10 yr was 92% for complete remission, 43% for partial remission, and 13% for no remission. CONCLUSION Even a partial remission in lupus nephritis is associated with a significantly better patient and renal survival compared with no remission.
منابع مشابه
نتایج درمان نفریت لوپوسی پرولیفراتیو مقاوم به درمان با سیکلوسپورین A
Background & Aims: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by various autoantibodies formation and immune complex deposition in various organs. Lupus nephritis is a common and severe manifestation of SLE that can lead to end stage renal disease and death. The aim of this study was to evaluate the long-term efficacy of cyclosporine A in the treat...
متن کاملاثر درمانی پالس سیکلوفسفامید وریدی در رمیسیون کلیوی بیماران مبتلا به نفریت لوپوسی پرولیفراتیو
Background: Lupus nephritis, especially diffuse proliferative type is one of the potentially life threatening disabling consequences of SLE that needs intensive and invasive treatment. As there is not enough information available about the results of Intravenous Cyclophamide (IVC) therapy on these patients in our country, this study was performed from 1997 to 2002 in Esfahan Azzahra Hospital. M...
متن کاملPredictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults.
BACKGROUND AND OBJECTIVES The prevalence and significance of remission and relapse in children, adolescents, and young adults with lupus nephritis in the United States are poorly understood. Patterns and predictors of disease progression in a southeastern U.S. pediatric cohort with severe lupus nephritis are presented. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS Individuals age 21 or less ...
متن کاملOutcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study
BACKGROUND The current standard for induction phase treatment of lupus nephritis is steroid combined with mycophenolate mofetil or pulse intravenous cyclophosphamide (IVC). The lowest dose of IVC recommended for induction therapy is that used in the Euro-Lupus Trial. It is not known whether same cumulative dose of IVC would be effective when given over six months. METHODS We carried out a pro...
متن کاملLupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?
Severe lupus nephritis is an aggressive disease that requires an aggressive approach to treatment. Recent randomized clinical trials showed that mycophenolate mofetil compared favorably with cyclophosphamide (traditional approach) for remission induction. Consequently, mycophenolate mofetil is now commonly recommended as first-line therapy. Nevertheless, the role of mycophenolate mofetil in tre...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical journal of the American Society of Nephrology : CJASN
دوره 3 1 شماره
صفحات -
تاریخ انتشار 2008